Overview

Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma

Status:
Unknown status

Trial end date:
2020-11-01

Target enrollment:

Participant gender:

Summary

The major aim of this research is to assess the feasibility, safety and effectiveness of CD19 CAR-T Cell Therapy for Relapsed/ Refractory Acute Lymphoblastic Leukemia/ B cell Lymphoma patients who have applied it.

Phase:

Phase 1

Details

Lead Sponsor:

Pinze Lifetechnology Co. Ltd.

Collaborators:

Chinese Academy of Sciences
Navy General Hospital, Beijing